

March 12, 2013



## Synthetic Biologics to Present at the 25th Annual ROTH Conference

ROCKVILLE, Md., March 12, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that its Chief Executive Officer, Jeffrey Riley, will present at the 25<sup>th</sup> Annual ROTH Conference being held on March 17-20, 2013 at the Ritz-Carlton, Laguna Niguel in Dana Point, California. Mr. Riley is scheduled to present on Tuesday, March 19, 2013 at 1:30 p.m. (Pacific Time).

A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the web at <http://wsw.com/webcast/roth27/syn/>. After the presentation, a replay will be archived and accessible for 30 days at the same website.

Mr. Riley, as well as Synthetic Biologics' Chief Financial Officer, C. Evan Ballantyne, and its Executive Vice President, Research & Development, John Monahan, Ph.D., will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

### About Synthetic Biologics, Inc.

Synthetic Biologics is a biotechnology company focused on the development of product candidates for serious infections and diseases. Synthetic Biologics is developing a biologic for the prevention of *C. difficile* infection, and a series of monoclonal antibodies for the treatment of serious infectious diseases, including pertussis and *Acinetobacter*. The Company is also developing a synthetic DNA-based therapy for the treatment of pulmonary arterial hypertension. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS, and is designing a clinical development pathway for the treatment of amyotrophic lateral sclerosis. For more information, please visit Synthetic Biologics' website at [www.syntheticbiologics.com](http://www.syntheticbiologics.com).

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your [iPhone and iPad](#) or your [Android mobile device](#).

SOURCE Synthetic Biologics, Inc.